Xeris Pharma Rg
Xeris Biopharma in Chicago develops ready-to-use glucagon (Gvoke) for severe hypoglycemia and therapies for periodic paralysis (Keveyis), Cushing's (Recorlev), plus a phase-3 once-weekly levothyroxine (XP-8121), targeting growth in chronic endocrine and neurological markets.
Headquarters: United States (USA)
- Website: Visit Site 🔗
- Type: Corporation
Company Profile
- Sector: Hospitals and Health Care
- Industry: Medical and Diagnostic Laboratories
- Employees: 394
- HQ: Chicago
Unlock the full potential.
Upgrade
Get access to Relative P/E Ratio Valuation Histogram.